Recently, Doron et al developed another adaptation to mFLOW-Seq (which they call multi-kingdom antibody profiling or multiKAP) to study host responses to endogenous gut mycobiota [28]
Recently, Doron et al developed another adaptation to mFLOW-Seq (which they call multi-kingdom antibody profiling or multiKAP) to study host responses to endogenous gut mycobiota [28]. cytometry, microbiome The gut, skin, vagina, and lungs are colonized by trillions of microbes that provide important biological functions for the host [2]. Of these sites, the intestinal microbiome contains the largest number (up to 1012 microbes per gram of intestinal contents) and diversity of commensal microbes. Microbes from the phyla and are the most abundant bacteria, generally comprising ~90% of adult intestinal microbiomes, followed by [3]. Commensal microbes stimulate the development of a healthy immune system and provide an important source of vitamins, increased ability to break down food, and protection from other pathogenic organisms [4]. Effective barriers at these mucosal sites exclude microbes with pathogenic potential from translocating to systemic sites, while allowing beneficial microbial communities to thrive [5]. In the gut, the barrier consists of an overlying layer of protective mucus enriched with mucosal antibodies and anti-microbial peptides, a single intestinal epithelial layer, and a variety of innate and adaptive immune cells including IgA and IgM antibody-secreting B cells [6]. Some of the commensal bacteria and fungi in a healthy microbiome have the potential to cause invasive disease, notably microbes such as (eg, and sp.) and microbes that localize closely to the mucosal surface (eg, segmented filamentous bacteria [SFB] and increases survival in a murine model of bacterial peritonitis [32]. Cohousing mice with different microbiomes (which effectively transfers microbiota between the mice via coprophagia) demonstrated that the introduction of specific commensal microbes increases serum IgA concentration by stimulating IgA producing plasma cells in the bone marrow [32]. In line with these findings, a recent study demonstrated that serum IgG from healthy mice decreases mortality in another model of bacterial peritonitis [30]. Analysis of serum IgG binding to commensal microbes demonstrated that IgG directed against murein lipoprotein (MLP), a major component of the outer membrane of Gram-negative bacteria, conferred protection against endogenous ([27]. Recently, Doron et al developed another adaptation to mFLOW-Seq (which they call multi-kingdom antibody profiling or multiKAP) to study host responses to endogenous gut mycobiota [28]. Since fungi typically represent a very small fraction of the fecal microbiome, the Dihydrofolic acid authors developed a clever approach to enrich for fungi from the fecal microbiome based on size fractionation and staining of fungal cell components with calcofluor white. They analyzed the IgA-bound fraction to define the mucosal immune response to commensal fungi and then added serum IgG to delineate which commensal fungi Dihydrofolic acid induce a systemic antibody response. These studies reveal a strong systemic IgG response to commensal in mice and humans. Colonization of mice with induces and partially protect against infection by other species, including the highly drug-resistant emerging pathogen [28]. These Dihydrofolic acid studies suggest that specific fungi induce serum IgG and IgA antibodies capable of binding to and preventing systemic fungal infection. To move towards clinical application of mFLOW-Seq, additional studies are needed to evaluate whether antibody binding to endogenous bacteria or fungi predicts risk for infection in patients. For those patients requiring antibody replacement therapy, there may be benefits to testing whether specific antibody preparations bind to a patients endogenous microbiota to prevent invasive infections. One limitation of mFLOW-Seq approach is that antibody responses typically take 7-10 days which limits utility during the early acute phase of infection and sensitivity of the humoral response to detect acute infection is diminished in some immunocompromised patients. Further mFLOW-Seq requires time to prepare, sort, and sequence Dihydrofolic acid antibody-coated microbes and expertise to perform and analyze these data. Further study is needed to determine if microbe-specific serum IgA, IgM, and IgG working in concert deliver the widest range of protection in immunoglobulin replacement therapies. Clinical trials of intravenous immunoglobulin (IVIG) for sepsis treatment have produced mixed results, but have not FA-H accounted for specificity towards the species or strain causing bacteremia [34]. Intriguingly, some studies found that antibody preparations that include IgM and IgG antibody isotypes may be better suited to treat patients with sepsis [35]. Maternal Antibodies and Risk for Enteric Infection and Inflammation Maternal factors, including in utero transfer of IgG, post-natal transfer of IgM, IgA, and IgG antibodies in breast milk, and vertical transmission of maternal microbiota, shape the early life microbiome and Dihydrofolic acid immune system thereby impacting susceptibility.